Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Up 8.2% – Time to Buy?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shot up 8.2% on Monday . The company traded as high as $28.70 and last traded at $28.57. Approximately 116,495 shares were traded during trading, a decline of 66% from the average session volume of 342,883 shares. The stock had previously closed at $26.40.

Analysts Set New Price Targets

Several research firms recently weighed in on KMTS. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research increased their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a report on Saturday. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.14.

Kestra Medical Technologies Stock Performance

The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a market cap of $1.66 billion, a P/E ratio of -11.67 and a beta of 0.58. The stock has a 50 day moving average price of $22.96 and a two-hundred day moving average price of $22.57.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million during the quarter. On average, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Timothy P. Moran sold 2,380 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.76, for a total transaction of $56,548.80. Following the sale, the insider owned 66,345 shares in the company, valued at approximately $1,576,357.20. This trade represents a 3.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the completion of the transaction, the insider owned 475,215 shares in the company, valued at approximately $11,652,271.80. The trade was a 9.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 211,877 shares of company stock worth $4,922,844. 5.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its position in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares during the last quarter. Rhumbline Advisers lifted its holdings in Kestra Medical Technologies by 7.3% during the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after buying an additional 874 shares during the period. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $31,000. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after buying an additional 1,392 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.